Slide 1: Result presentation Q4/2021
17 February 2022, Seppo Kopsala, CEO / Lars Lindqvist, CFO Result presentation Q4/2021
Slide 2: Highlights
Highlights OPT@MED
Slide 3: Highlights FY 2021
FY 2021 Revenue increased by over 14.1 percent to EUR 14,850 (13,011) driven by 1. continued growth in North America and Highlights FY 2021 Europe as well as from OEM customers. Gross Margin increased to 71.1 percent 2. from 68.8 percent last year. China started the year very well driven by Phoebus/
Slide 4: Highlights Q4-2021
Q4 2021 China: China pressed down the revenue trajectory: no new deliveries made 1. to China during this or the previous quarter Highlights Q4-2021 Other areas: all other areas performed well. Very strong growth in the US; 2. Europe, OEM and Software recurring revenue all grew Clinical Trial: the re
Slide 5: Focus areas
Focus areas China: • Phoebus’ exclusivity terminated and a credit risk accrual made • New national guidelines published recommending made-in- China fundus cameras • A negative impact expected on Optomed’s growth in H1’22 USA: • Sales grew strongly in both direct sales and our expanding distribution
Slide 6: Clinical Trial
Clinical Trial • 91.9% sensitivity • 93.6% specificity • 99+% imageability • Only a single image per eye Optomed and AEYE Health are seeking FDA clearance for the solution CAUTION - Investigational device. Limited by United States law to investigational use.
Slide 7: Q4/2021 Financial highlights (KEUR)
Q4/2021 Financial highlights (KEUR) Q4/2021 Q4/2020 Change Revenue 3,552 4,041 -12.1% Gross profit 1) 2,407 2,809 -14.3% Gross margin 2) 67.8% 69.5% -170 bps Adjusted EBITDA -1,528 -62 -2374.1% Adjusted EBITDA margin -43.0% -1.5% -4150 bps Net profit/ loss -1,936 -652 -196.9% Earnings per share -0.1
Slide 8: 1-12/2021 Financial highlights (KEUR)
1-12/2021 Financial highlights (KEUR) 1-12/2021 1-12/2020 Change Revenue 14,850 13,011 14.1% Gross profit 1) 10,558 8,955 17.9% Gross margin 2) 71.1% 68.8% +230 bps Adjusted EBITDA -2,002 -733 -173.2% Adjusted EBITDA margin -13.5% -5.6% -790 bps Net profit/ loss -4,249 -3,177 -33.8% Earnings per sha
Slide 9: Devices segment highlights
Devices segment highlights OPT@MED
Slide 10: Devices segment highlights
No hardware deliveries were Q4/2021 Q4/2020 Change 1. made to China Devices segment highlights Revenue 1,329 1,738 -23.6% North America, European markets continued strong 2. growth as well as sales the Gross profit 764 990 -22.8% OEM channel Gross margin 57.5% 56.9% 60 bps The result is impacted by
Slide 11: Devices Segment 1-12/2021 financials
Devices Segment 1-12/2021 financials 1-12/2021 1-12/2020 Change % Revenue 5,839 5,097 14.5% Gross profit 4,139 2,862 44.6% Gross margin 70.9% 56.1% 148 bps EBITDA -1,014 -251 -304.5% EBITDA margin -17.4% -4.9% -125 bps
Slide 12: Software segment highlights
Software segment highlights
Slide 13: Software segment highlights
Q4/2021 Q4/2020 Change Stable quarter even though the revenue decreased by 1. Software segment highlights 3.5 percent while the comparison in 2020 was Revenue 2,223 2,303 -3.5% exceptionally strong Gross profit 1,643 1,819 -9.7% Drivers included screening and workflow software 2. deliveries to new c
Slide 14: Software Segment 1-12/2021 financials
Software Segment 1-12/2021 financials 1-12/2021 1-12/2020 Change % Revenue 9,011 7,913 13.9% Gross profit 6,420 6,093 5.4% Gross margin 71.2% 77.0% -580 bps EBITDA 1,855 1,926 -3.7% EBITDA margin 20.6% 24.3% -370 bps
Slide 15: Outlook
Outlook
Slide 16: Outlook 2022
Outlook 2022 Optomed expects its full year 2022 revenue to grow compared to 2021 (Announced 17 February 2022)
Slide 17: Financial targets
Financial targets Revenue Growth Adjusted EBITDA Optomed’s medium-term target is to deliver Optomed’s target is to prioritise a double-digit annual organic revenue investments in the organisation to growth. In the long-term Optomed’s target support growth in the medium-term and is to deliver an aver
Slide 18: Balance sheet
Balance sheet 31/12 2021 31/12 2020 Balance sheet ASSETS Goodwill 4,256 4,256 Development costs 6,338 5,667 • Equity ratio of 58.8 (64.6) percent Other intangible assets 2,380 2,831 Total intangible assets 12,975 12,753 • Total borrowings of EUR 7.0 (6.5) Total tangible assets 1,651 1,535 million. N
Slide 19: Cash flow
Q4 2021 Q4 2020 Cash flow Loss for the financial year -1,936 -652 Cash flows before change -906 42 • Cash flow from operating in net working capital activities amounted to Change in net working capital 474 529 EUR -0.5 (0.4) million Cash flows before finance items -432 571 Cash flows from finance it
Slide 20: Optomed's goal is to improve access to eye screening globally
“ Optomed’s goal is to improve access to eye screening globally by taking them to primary care Expansion into new Opening new customer Bringing AI-integrated health geographical markets segments: primary care screening to the market
Slide 21: Appendix
Appendix
Slide 22: Cash flow 1-12/2021
Cash flow 1-12/2021 1-12 2021 1-12 2020 Loss for the financial year -4,249 -3,177 Cash flows before change in net working capital -1,041 -377 Change in net working capital -1,047 -1,990 Cash flows before finance items -2,811 -2,367 Cash flows from finance items -129 -434 Net cash from operating acti